Skip to main navigation
Skip to search
Skip to main content
Keio University Home
Help & FAQ
Link opens in a new tab
English
日本語
Search content at Keio University
Home
Profiles
Research units
Research output
Adjuvant chemotherapy for breast cancer--a current controversy
Hiromitsu Jinno
, Tadashi Ikeda
, Kouichi Kubouchi
, Kiyoshi Fujiwara
, Masaki Kitajima
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjuvant chemotherapy for breast cancer--a current controversy'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Breast Cancer
100%
Adjuvant Chemotherapy
100%
Survival Rate
33%
High Dose
33%
Doxorubicin
33%
Disease-free Survival
33%
High Risk
33%
Poor Prognosis
33%
Meta-analysis
33%
Distant Metastasis
33%
Radiation Therapy
33%
Dose Level
33%
Breast Reconstruction
33%
Taxanes
33%
Nodal Status
33%
Survival Benefit
33%
Early Breast Cancer
33%
Epirubicin
33%
High Survival
33%
ER Status
33%
Dose-dense Therapy
33%
Anthracycline Therapy
33%
Patients Receiving Chemotherapy
33%
Medicine and Dentistry
Breast Cancer
100%
Adjuvant Chemotherapy
100%
Survival Rate
33%
Doxorubicin
33%
Disease Free Survival
33%
Meta-Analysis
33%
Distant Metastasis
33%
Drug Megadose
33%
Anthracycline
33%
Quadrantectomy
33%
Epirubicin
33%
Dose Densification
33%
Diseases
33%
Radiation Therapy
33%
Chemotherapy
33%